Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
A Polish security analyst has rejected Russian media claims that NATO’s annual Steadfast Noon nuclear readiness exercise violates international law.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback